2012 Midyear Clinical Meeting
Click here to go to the previous page
New Oral Anticoagulants: A Balancing Act Between Safety and Efficacy
Track:
New Practitioners Sessions (CE)
Program Code: 309-L01
Date: Sunday, December 2, 2012
Time: 3:30 PM to 5:00 PM EST
Location:
South Seas E, Level 3, South Convention Center
PRESENTER(S):
Click the plus sign to see more detailed information about each speaker.
James Groce, III,
PharmD, CACP, Professor,
Campbell University College of Pharmacy & Health Sciences
|
James B. Groce III, PharmD, is Professor, Department of Pharmacy Practice at Campbell University College of Pharmacy and Health Sciences. He also is Clinical Assistant Professor of Medicine at the University of North Carolina School of Medicine, and Clinical Pharmacy Specialist-Anticoagulation at the Moses H. Cone Memorial Hospital in Greensboro, North Carolina.
Throughout his career in pharmacy, Dr. Groce has been published and cited on important healthcare topics in numerous peer-reviewed medical and pharmacy journals as well as textbooks of pharmacy. He has served as principal investigator on a number of studies, including many that supported the concept of outpatient treatment of venous thromboembolism. His published research has also evaluated the pharmacoeconomics of using low molecular weight heparins for outpatient treatment of deep venous thrombosis (DVT) in a community hospital setting, various heparin weight-based dosing nomograms, and the utility of heparin level determinations and outcomes analysis.
Dr. Groces colleagues and the public have benefited from his unique expertise. He served upon the Technical Advisory Panel of The Joint Commission/National Quality Forum for creation of core measures for prevention and treatment of venous thromboembolism which culminated in National Hospital Quality Measures for venous thromboembolism October 1, 2009. All these activities have earned Dr. Groce national and global recognition for his contributions to this clinical area of interest and research.
|
Carrie Oliphant,
PharmD, BCPS (AQ Cardiology), Cardiology Clinical Specialist,
Methodist University Hospital
|
Carrie Oliphant, Pharm.D., BCPS (AQ Cardiology)
Dr. Oliphant is a Clinical Pharmacy Specialist Cardiology/Anticoagulation at Methodist University Hospital in Memphis, TN. She is also an Associate Professor at the University of Tennessee College of Pharmacy. Dr. Oliphant received her BS Pharmacy and Pharm.D. degrees at Duquesne University in Pittsburgh, PA. Following graduation, she completed a PGY-1 residency at Methodist University Hospital. She is a Board Certified Pharmacotherapy Specialist with Added Qualifications in Cardiology. She has practiced in Cardiology for more than 10 years and precepted over 40 Pharmacy students and 50 Pharmacy residents on a Cardiology rotation.
Her main areas of interest are Acute Coronary Syndrome, Antiplatelets and Anticoagulants.
|
Matthew Strum,
PharmD, BCACP, Clinical Assistant Professor,
University of Mississippi School of Pharmacy
|
Matthew Strum, Pharm.D., BCACP, CDE is a Clinical Assistant Professor in the Department of Pharmacy Practice at the University of Mississippi School of Pharmacy. He also is a clinical pharmacist at Oxford Endocrinology Consultants.
Dr. Strum's academic responsibilities include Pharmacy Practice Skills Lab III/IV, non-prescription medications, and Problem Solving I-IV. Dr. Strum also precepts students on an Ambulatory Care Introductory Pharmacy Practice Experience rotation in the third professional year and on an Ambulatory Care Advanced Pharmacy Practice Experience rotation during the fourth professional year.
Dr. Strum received his Bachelor of Science in Pharmaceutical Sciences and Doctor of Pharmacy degrees from the University of Mississippi School of Pharmacy. He completed a pharmacy practice residency emphasizing ambulatory care at The Regional Medical Center at Memphis where he concentrated his work in diabetes management and anticoagulation. Dr. Strum is a Board Certified Ambulatory Care Pharmacist, has been a Certified Diabetes Educator for over 10 years, and formerly a Certified Anticoagulation Care Provider. His area of interest is in ambulatory care, specifically in diabetes management, dyslipidemia, and hypertension. Dr. Strum is actively involved in several local and national organizations including the Mississippi Pharmacists Association, Mississippi Society of Health-System Pharmacists, ASHP, ACCP, and AADE.
|
Daniel Witt,
PharmD, BCPS, Sr. Manager Clinical Pharmacy Research & Applied Pharmacogenomics,
Kaiser Permanente
|
Received BS in Pharmacy from University of Utah and PharmD from University of Washington. Clinical Pharmacy Residency from University of Washington and Harborview Medical Centers, Specialty Primary Care Residency at University of Washington Family Medicine Clinic. Has worked at Kaiser Permanente Colorado since 1993. Was responsible for development of Clinical Pharmacy Anticoagulation Service which provides comprehensive anticoagulation therapy management for over 8,200 patients. Is currently Senior Manager, Clinical Pharmacy Research and Applied Pharmacogenomics. Has published numerous original research articles and book chapters regarding anticoagulation therapy. Is member of ACCP Research Institutes Board of Trustees, on the Anticoagulation Forums Board of Directors, and recently served as a panelist for the 2012 Chest Supplement Consensus Conference on Antithrombotic Therapy.
|
PROGRAM CHAIR:
Click the plus sign to see more detailed information about each speaker.
Joel Marrs,
PharmD, BCPS, Assistant Professor,
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
|
Dr. Joel Marrs is an Assistant Professor in the Department of Clinical Pharmacy at the University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences. He is a Board Certified Pharmacotherapy Specialist with Added Qualifications in Cardiology. In addition he is a Clinical Lipid Specialist recognized by the Accreditation Council for Clinical Lipidology and a Fellow of the National Lipid Association (NLA). Currently, he is a Board Member of the Southwest Chapter of the NLA. Dr. Marrs received his PharmD degree from Butler University. Following his PharmD degree he completed a postgraduate year 1 (PGY1) pharmacy practice residency at Mount Carmel Medical Center in Columbus, Ohio and a PGY2 Family Medicine Specialty residency at the University of Colorado in Denver, Colorado. In his current position, Dr. Marrs practices as a clinical pharmacy specialist with Denver Health in an internal medicine clinic where he focuses on cardiovascular and metabolic pharmacotherapy.
|
Description
Safety and Efficacy Analysis of New Oral Anticoagulants versus Warfarin, Carrie Oliphant, PharmD, BCPS (AQ Cardiology)
Comparison of Reversibility Practices for New Oral Anticoagulants versus Warfarin, James B. Groce, III, PharmD, CACP
Optimal Management of New Oral Anticoagulants during Transitions between the Inpatient and Outpatient Setting, Daniel M. Witt, PharmD, BCPS
- Compare anticoagulation reversibility practices between warfarin, dabigatran, and rivaroxaban.
- Describe safety data comparing the bleeding risk between warfarin, dabigatrin, and rivaroxaban.
- Describe stroke prevention data in patients with nonvalvular atrial fibrillation treated with warfarin, dabigatrin, or rivaroxaban.
- Determine optimal practices for the safe use of new oral anticoagulants in the inpatient setting and the transition to outpatient setting.
